CA2728562C - Methods for treating multiple sclerosis using antisense oligonucleotides - Google Patents
Methods for treating multiple sclerosis using antisense oligonucleotides Download PDFInfo
- Publication number
- CA2728562C CA2728562C CA2728562A CA2728562A CA2728562C CA 2728562 C CA2728562 C CA 2728562C CA 2728562 A CA2728562 A CA 2728562A CA 2728562 A CA2728562 A CA 2728562A CA 2728562 C CA2728562 C CA 2728562C
- Authority
- CA
- Canada
- Prior art keywords
- multiple sclerosis
- methods
- antisense oligonucleotides
- treating multiple
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title 1
- 239000000074 antisense oligonucleotide Substances 0.000 title 1
- 238000012230 antisense oligonucleotides Methods 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13297308P | 2008-06-23 | 2008-06-23 | |
| US61/132,973 | 2008-06-23 | ||
| PCT/US2009/003760 WO2010008474A2 (en) | 2008-06-23 | 2009-06-23 | Methods for treating multiple sclerosis using antisense oligonucleotides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2728562A1 CA2728562A1 (en) | 2010-01-21 |
| CA2728562C true CA2728562C (en) | 2018-10-23 |
Family
ID=41550900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2728562A Active CA2728562C (en) | 2008-06-23 | 2009-06-23 | Methods for treating multiple sclerosis using antisense oligonucleotides |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8415314B2 (enExample) |
| EP (2) | EP2318424B1 (enExample) |
| JP (2) | JP5988581B2 (enExample) |
| AU (1) | AU2009271678B2 (enExample) |
| CA (1) | CA2728562C (enExample) |
| DK (2) | DK2937358T3 (enExample) |
| ES (2) | ES2532404T3 (enExample) |
| WO (1) | WO2010008474A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2532404T3 (es) | 2008-06-23 | 2015-03-26 | Antisense Therapeutics Ltd | Métodos para tratar la esclerosis múltiple usando oligonucleótidos antisentido |
| AU2011301712C1 (en) * | 2010-09-17 | 2017-01-05 | Antisense Therapeutics Ltd | Method for reducing the number of certain circulating leukocytes in a human subject |
| EP3294889B1 (en) * | 2015-05-11 | 2021-01-06 | Murdoch University | Multiple sclerosis treatment |
| AU2018286483C1 (en) * | 2017-06-16 | 2024-10-31 | Antisense Therapeutics Ltd | Methods for treating multiple sclerosis using antisense oligonucleotides |
| KR20210018820A (ko) * | 2018-05-04 | 2021-02-18 | 안티센스 테라퓨틱스 엘티디 | 치료 용도 및 방법 |
| WO2020223762A1 (en) * | 2019-05-06 | 2020-11-12 | Antisense Therapeutics Ltd | Methods for treating muscular dystrophy using inhibitory oligonucleotides to cd49d |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242591B1 (en) * | 1997-10-15 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Synthesis of sulfurized 2'-substituted oligonucleotides |
| US5968826A (en) * | 1998-10-05 | 1999-10-19 | Isis Pharmaceuticals Inc. | Antisense inhibition of integrin α4 expression |
| WO2005108610A2 (en) * | 2004-04-05 | 2005-11-17 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for the selection of subjects for multiple sclerosis therapy |
| JP2008516991A (ja) * | 2004-10-20 | 2008-05-22 | アンチセンス セラピューティクス リミテッド | インテグリンα４発現のアンチセンス調節 |
| ES2532404T3 (es) | 2008-06-23 | 2015-03-26 | Antisense Therapeutics Ltd | Métodos para tratar la esclerosis múltiple usando oligonucleótidos antisentido |
-
2009
- 2009-06-23 ES ES09798248.2T patent/ES2532404T3/es active Active
- 2009-06-23 EP EP09798248.2A patent/EP2318424B1/en not_active Not-in-force
- 2009-06-23 DK DK15155831.9T patent/DK2937358T3/da active
- 2009-06-23 WO PCT/US2009/003760 patent/WO2010008474A2/en not_active Ceased
- 2009-06-23 AU AU2009271678A patent/AU2009271678B2/en not_active Ceased
- 2009-06-23 ES ES15155831T patent/ES2699891T3/es active Active
- 2009-06-23 US US12/456,883 patent/US8415314B2/en not_active Expired - Fee Related
- 2009-06-23 EP EP15155831.9A patent/EP2937358B1/en active Active
- 2009-06-23 JP JP2011516297A patent/JP5988581B2/ja not_active Expired - Fee Related
- 2009-06-23 CA CA2728562A patent/CA2728562C/en active Active
- 2009-06-23 DK DK09798248T patent/DK2318424T3/en active
-
2013
- 2013-03-22 US US13/848,811 patent/US8759314B2/en active Active
-
2014
- 2014-10-09 JP JP2014208153A patent/JP6131230B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015044824A (ja) | 2015-03-12 |
| EP2318424B1 (en) | 2015-02-25 |
| DK2937358T3 (da) | 2019-01-02 |
| AU2009271678B2 (en) | 2013-09-19 |
| EP2318424A4 (en) | 2012-12-26 |
| JP6131230B2 (ja) | 2017-05-17 |
| WO2010008474A2 (en) | 2010-01-21 |
| JP2011525531A (ja) | 2011-09-22 |
| ES2532404T3 (es) | 2015-03-26 |
| WO2010008474A3 (en) | 2010-04-22 |
| AU2009271678A1 (en) | 2010-01-21 |
| US8415314B2 (en) | 2013-04-09 |
| DK2318424T3 (en) | 2015-04-07 |
| WO2010008474A4 (en) | 2011-01-27 |
| EP2937358B1 (en) | 2018-09-19 |
| JP5988581B2 (ja) | 2016-09-07 |
| US20100119480A1 (en) | 2010-05-13 |
| EP2937358A1 (en) | 2015-10-28 |
| US20130345293A1 (en) | 2013-12-26 |
| CA2728562A1 (en) | 2010-01-21 |
| ES2699891T3 (es) | 2019-02-13 |
| EP2318424A2 (en) | 2011-05-11 |
| US8759314B2 (en) | 2014-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009045356A8 (en) | Microrna compositions in the treatment of vegf-mediated disorders | |
| WO2009001359A3 (en) | Compositions and methods for inhibiting expression of pro-apoptotic genes | |
| WO2007081975A3 (en) | Method of treating multiple sclerosis | |
| MX2013009191A (es) | Oligonucleotidos antisentido. | |
| EP4371560A3 (en) | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof | |
| MX2009005527A (es) | Metodos para el tratamiento de hipercolesterolemia. | |
| MX2010002312A (es) | Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis. | |
| WO2008022256A3 (en) | Methods and compositions for preventing or treating age-related diseases | |
| TNSN08140A1 (enExample) | ||
| IL201479A (en) | Use of tapentadol for the preparation of pain medication | |
| CA2728562C (en) | Methods for treating multiple sclerosis using antisense oligonucleotides | |
| EA201290859A1 (ru) | Лечение люпус-артрита с использованием лаквинимода | |
| MX346186B (es) | Inhibidores de proteina cinasas. | |
| MX2009005649A (es) | Tratamiento para mieloma multiple. | |
| MY168763A (en) | Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases | |
| WO2011009039A3 (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease | |
| WO2010053861A3 (en) | Biologically active amides | |
| WO2008097924A3 (en) | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders | |
| AU2009279857A8 (en) | Modulation of toll-like receptor 3 expression by antisense oligonucleotides | |
| WO2007106884A3 (en) | Methods of treating muscular wasting diseases using nf-kb activation inhibitors | |
| WO2008030795A3 (en) | Compositions and methods for inhibition of tyrosine kinases | |
| WO2008012796A3 (en) | Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation | |
| MX2010008490A (es) | Triazolopiridazinas como inhibidores de par1, su produccion y su uso como medicamentos. | |
| TNSN08506A1 (en) | Substituted carboxamides | |
| ATE500226T1 (de) | Aripiprazolhemifumarat und verfahren zu dessen herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140611 |